FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4247361750> ?p ?o ?g. }

• W4247361750 endingPage "516" @default.
• W4247361750 startingPage "509" @default.
• W4247361750 abstract "No AccessJournal of UrologyAdult Urology1 Aug 2009Denosumab Treatment of Prostate Cancer With Bone Metastases and Increased Urine N-Telopeptide Levels After Therapy With Intravenous Bisphosphonates: Results of a Randomized Phase II Trialis companion ofDenosumab Treatment of Prostate Cancer With Bone Metastases and Increased Urine N-Telopeptide Levels After Therapy With Intravenous Bisphosphonates: Results of a Randomized Phase II Trial Karim Fizazi, Linda Bosserman, Guozhi Gao, Tomas Skacel, and Richard Markus Karim FizaziKarim Fizazi Institut Gustave Roussy and University of Paris XI, Villejuif, France Financial interest and/or other relationship with Amgen, Novartis, AstraZeneca, Sanofi-Aventis, Ipsen-Beaufour, Pharmion, Bristol Myers Squibb and Takeda. More articles by this author , Linda BossermanLinda Bosserman Wilshire Oncology Medical Group, La Verne, California Financial interest and/or other relationship with Amgen and Pfizer. More articles by this author , Guozhi GaoGuozhi Gao Amgen Inc., San Francisco, California Financial interest and/or other relationship with Amgen. More articles by this author , Tomas SkacelTomas Skacel Amgen (Europe) GmbH, Zug, Switzerland Financial interest and/or other relationship with Amgen. More articles by this author , and Richard MarkusRichard Markus Amgen Inc., Thousand Oaks, California Financial interest and/or other relationship with Amgen. More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2009.04.023AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Patients with bone metastases have high rates of RANKL driven bone resorption and an increased risk of skeletal morbidity. Osteoclast mediated bone resorption can be assessed by measuring urine N-telopeptide and can be inhibited by denosumab, a fully human antibody against RANKL. Materials and Methods: Eligible patients (111) had bone metastases from prostate cancer, other solid tumors or multiple myeloma, 1 or more bone lesions and urine N-telopeptide greater than 50 nM bone collagen equivalents per mM creatinine (urine N-telopeptide greater than 50) despite the use of intravenous bisphosphonates. Patients were stratified by cancer type and screening urine N-telopeptide, and randomized to continue intravenous bisphosphonates every 4 weeks or receive 180 mg subcutaneous denosumab every 4 weeks or 180 mg every 12 weeks. The primary end point was the proportion of patients with urine N-telopeptide less than 50 at week 13. We report the efficacy results for the subset of patients with prostate cancer. Results: Patients with prostate cancer represented 45% (50 of 111) of the study population. At week 13, 22 of 32 (69%) patients in the denosumab arms had urine N-telopeptide less than 50 vs 3 of 16 (19%) in the intravenous bisphosphonates cohort. At week 25, 22 of 32 (69%) denosumab treated patients continued to have urine N-telopeptide less than 50 vs 5 of 16 (31%) treated with intravenous bisphosphonates. Grade 4, asymptomatic, reversible hypophosphatemia, possibly related to denosumab, was reported in 1 patient. Conclusions: In patients with prostate cancer related bone metastases and increased urine N-telopeptide despite intravenous bisphosphonate treatment, denosumab normalized urine N-telopeptide levels more frequently than ongoing intravenous bisphosphonates. References 1 : Health statistics and health information systems: Revised Global Burden of Disease (GBD) 2002 estimates. http://www.who.int/healthinfo/bodgbd2002revised/en/index.html. Accessed May 15, 2008. Google Scholar 2 : Skeletal complications of malignancy. Cancer1997; 80: 1588. Google Scholar 3 : Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst2005; 97: 59. Google Scholar 4 : Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol2000; 157: 435. Google Scholar 5 : Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res2003; 9: 2587. Google Scholar 6 : The effects of osteoprotegerin on the mechanical properties of rat bone. J Mater Sci Mater Med2001; 12: 583. Google Scholar 7 : Analysis of three-dimensional microarchitecture and degree of mineralization in bone metastases from prostate cancer using synchrotron microcomputed tomography. Bone2004; 35: 432. Google Scholar 8 : Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res2001; 61: 5652. Google Scholar 9 : Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol1991; 68: 74. Google Scholar 10 : Skeletal biology. In: Skeletal Tissue Mechanics. Edited by . New York: Springer1998: 29. Google Scholar 11 : Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol2000; 18: 1570. Google Scholar 12 : Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer2003; 89: 2031. Google Scholar 13 : Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol2008; 19: 420. Google Scholar 14 : A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res2006; 12: 1221. Google Scholar 15 : Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol2009; 27: 1564. Google Scholar 16 : Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. Urology2007; 70: 315. Google Scholar 17 : Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res2008; 14: 6690. Google Scholar 18 : Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol2009; 27: 2429. Google Scholar 19 : The role of Src in prostate cancer. Ann Oncol2007; 18: 1765. Google Scholar 20 : Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res2006; 12: 6296s. Google Scholar © 2009 by American Urological AssociationFiguresReferencesRelatedDetailsRelated articlesJournal of Urology10 Nov 2018Denosumab Treatment of Prostate Cancer With Bone Metastases and Increased Urine N-Telopeptide Levels After Therapy With Intravenous Bisphosphonates: Results of a Randomized Phase II Trial Volume 182Issue 2August 2009Page: 509-516 Advertisement Copyright & Permissions© 2009 by American Urological AssociationKeywordsRANK ligandosteoclastsprostatic neoplasmsurinary N-telopeptide of type I collagendenosumabhumanAcknowledgmentsTing Chang, PhD and Sue Hudson from Amgen Inc. provided writing assistance. Several investigators treated patients with prostate cancer in this study, including Zenoma Jablońska, Wroclaw, Poland; Xavier Mariette, Le Kremlin Bicêtre, Cedex, France; Tirzo Suarez, Merida, Yucatan, Mexico; Jesus Lopez-Hernandez, Durango, Mexico; Ana Rodriguez, Guadalajara, Jalisco, Mexico; Antonio Garcia-Juarez, Santiago de Queretaro, Queretaro, Mexico; Jorge Robles-Avina, Mexico City, Mexico; and Francisco Rosales Hernandez, Torreon, Coahuila, Mexico.MetricsAuthor Information Karim Fizazi Institut Gustave Roussy and University of Paris XI, Villejuif, France Financial interest and/or other relationship with Amgen, Novartis, AstraZeneca, Sanofi-Aventis, Ipsen-Beaufour, Pharmion, Bristol Myers Squibb and Takeda. More articles by this author Linda Bosserman Wilshire Oncology Medical Group, La Verne, California Financial interest and/or other relationship with Amgen and Pfizer. More articles by this author Guozhi Gao Amgen Inc., San Francisco, California Financial interest and/or other relationship with Amgen. More articles by this author Tomas Skacel Amgen (Europe) GmbH, Zug, Switzerland Financial interest and/or other relationship with Amgen. More articles by this author Richard Markus Amgen Inc., Thousand Oaks, California Financial interest and/or other relationship with Amgen. More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W4247361750 created "2022-05-12" @default.
• W4247361750 creator A5007779528 @default.
• W4247361750 creator A5073137051 @default.
• W4247361750 creator A5076180960 @default.
• W4247361750 creator A5078398114 @default.
• W4247361750 creator A5089040548 @default.
• W4247361750 date "2009-08-01" @default.
• W4247361750 modified "2023-10-18" @default.
• W4247361750 title "Denosumab Treatment of Prostate Cancer With Bone Metastases and Increased Urine N-Telopeptide Levels After Therapy With Intravenous Bisphosphonates: Results of a Randomized Phase II Trial" @default.
• W4247361750 cites W1928668153 @default.
• W4247361750 cites W194340635 @default.
• W4247361750 cites W1982915376 @default.
• W4247361750 cites W2064230636 @default.
• W4247361750 cites W2093871127 @default.
• W4247361750 cites W2095170176 @default.
• W4247361750 cites W2102352213 @default.
• W4247361750 cites W2103904089 @default.
• W4247361750 cites W2115962082 @default.
• W4247361750 cites W2133551420 @default.
• W4247361750 cites W2137881146 @default.
• W4247361750 cites W2141272738 @default.
• W4247361750 cites W2146217561 @default.
• W4247361750 cites W2149547695 @default.
• W4247361750 cites W2152409486 @default.
• W4247361750 cites W2157820793 @default.
• W4247361750 doi "https://doi.org/10.1016/j.juro.2009.04.023" @default.
• W4247361750 hasPublicationYear "2009" @default.
• W4247361750 type Work @default.
• W4247361750 citedByCount "67" @default.
• W4247361750 countsByYear W42473617502012 @default.
• W4247361750 countsByYear W42473617502013 @default.
• W4247361750 countsByYear W42473617502014 @default.
• W4247361750 countsByYear W42473617502015 @default.
• W4247361750 countsByYear W42473617502016 @default.
• W4247361750 countsByYear W42473617502017 @default.
• W4247361750 countsByYear W42473617502018 @default.
• W4247361750 countsByYear W42473617502019 @default.
• W4247361750 countsByYear W42473617502020 @default.
• W4247361750 countsByYear W42473617502021 @default.
• W4247361750 countsByYear W42473617502022 @default.
• W4247361750 crossrefType "journal-article" @default.
• W4247361750 hasAuthorship W4247361750A5007779528 @default.
• W4247361750 hasAuthorship W4247361750A5073137051 @default.
• W4247361750 hasAuthorship W4247361750A5076180960 @default.
• W4247361750 hasAuthorship W4247361750A5078398114 @default.
• W4247361750 hasAuthorship W4247361750A5089040548 @default.
• W4247361750 hasConcept C121608353 @default.
• W4247361750 hasConcept C125870589 @default.
• W4247361750 hasConcept C126322002 @default.
• W4247361750 hasConcept C126894567 @default.
• W4247361750 hasConcept C131075544 @default.
• W4247361750 hasConcept C143998085 @default.
• W4247361750 hasConcept C160160445 @default.
• W4247361750 hasConcept C168563851 @default.
• W4247361750 hasConcept C181199279 @default.
• W4247361750 hasConcept C185592680 @default.
• W4247361750 hasConcept C2776286101 @default.
• W4247361750 hasConcept C2776541429 @default.
• W4247361750 hasConcept C2780026642 @default.
• W4247361750 hasConcept C2780192828 @default.
• W4247361750 hasConcept C55493867 @default.
• W4247361750 hasConcept C71924100 @default.
• W4247361750 hasConceptScore W4247361750C121608353 @default.
• W4247361750 hasConceptScore W4247361750C125870589 @default.
• W4247361750 hasConceptScore W4247361750C126322002 @default.
• W4247361750 hasConceptScore W4247361750C126894567 @default.
• W4247361750 hasConceptScore W4247361750C131075544 @default.
• W4247361750 hasConceptScore W4247361750C143998085 @default.
• W4247361750 hasConceptScore W4247361750C160160445 @default.
• W4247361750 hasConceptScore W4247361750C168563851 @default.
• W4247361750 hasConceptScore W4247361750C181199279 @default.
• W4247361750 hasConceptScore W4247361750C185592680 @default.
• W4247361750 hasConceptScore W4247361750C2776286101 @default.
• W4247361750 hasConceptScore W4247361750C2776541429 @default.
• W4247361750 hasConceptScore W4247361750C2780026642 @default.
• W4247361750 hasConceptScore W4247361750C2780192828 @default.
• W4247361750 hasConceptScore W4247361750C55493867 @default.
• W4247361750 hasConceptScore W4247361750C71924100 @default.
• W4247361750 hasIssue "2" @default.
• W4247361750 hasLocation W42473617501 @default.
• W4247361750 hasOpenAccess W4247361750 @default.
• W4247361750 hasPrimaryLocation W42473617501 @default.
• W4247361750 hasRelatedWork W1501688191 @default.
• W4247361750 hasRelatedWork W2017374472 @default.
• W4247361750 hasRelatedWork W2024311986 @default.
• W4247361750 hasRelatedWork W2059294441 @default.
• W4247361750 hasRelatedWork W2568045406 @default.
• W4247361750 hasRelatedWork W2837810867 @default.
• W4247361750 hasRelatedWork W2906311539 @default.
• W4247361750 hasRelatedWork W4247326581 @default.
• W4247361750 hasRelatedWork W4256514411 @default.
• W4247361750 hasRelatedWork W659521541 @default.
• W4247361750 hasVolume "182" @default.
• W4247361750 isParatext "false" @default.
• W4247361750 isRetracted "false" @default.
• W4247361750 workType "article" @default.